NFKB1 and deep vein thrombosis: Therefore, our data support the notion that NF-kB transcription factor may be considered as an excellent therapeutic target for cancer patients, especially those complicated by DVT and treatment with NF-kB inhibitors may corroborate the efficacy of chemotherapeutic agents.